Form 8-K - Current report:
SEC Accession No. 0001213900-17-004962
Filing Date
2017-05-11
Accepted
2017-05-11 17:00:15
Documents
2
Period of Report
2017-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k050517_actiniumpharma.htm 8-K 29122
2 AMENDMENT TO AMENDED AND RESTATED CONSULTING AGREEMENT, DATED MAY 5, 2017, BETWE f8k050517ex10i_actinium.htm EX-10.1 6411
  Complete submission text file 0001213900-17-004962.txt   36908
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 17835208
SIC: 2834 Pharmaceutical Preparations